๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Levoleucovorin

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 5 trials in our USA, China, UK and Ireland registers that name Levoleucovorin as an intervention. Synced 24 Sep 2026
5Trials tracked
4Recruiting now
3Lead sponsors
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Levoleucovorin is named as a drug or biological intervention in 5 clinical trials in our USA, China, UK and Ireland trial registers, 4 of which are recruiting. Lead sponsors include Merck Sharp & Dohme LLC (3), Seagen, a wholly owned subsidiary of Pfizer (1) and Taiho Oncology, Inc. (1). Registered phases: Phase 1/2, Phase 3 and Phase 2. Conditions studied include Colorectal Neoplasms; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma.

01

Clinical trials of Levoleucovorin

5 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Phase 3 Recruiting Seagen, a wholly owned subsidiary of Pfizer Ireland, UK, USA, China
NCT06428409 A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) (ClinicalTrials.gov ↗)
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Phase 1/2 Recruiting Merck Sharp & Dohme LLC UK, USA, China
NCT06469944 Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (ClinicalTrials.gov ↗)
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms
Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT06780111 Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (ClinicalTrials.gov ↗)
Esophageal Squamous Cell Carcinoma
Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (ClinicalTrials.gov ↗)
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer
Phase 2 Active, closed Taiho Oncology, Inc. USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

13 conditions
Condition (as registered)Trials
Colorectal Neoplasms1
Colorectal Cancer1
Pancreatic Ductal Adenocarcinoma1
Biliary Tract Cancer1
Gastroesophageal Junction1
Gastroesophageal Adenocarcinoma1
Esophageal Neoplasms1
Esophageal Cancer1
Esophageal Squamous Cell Carcinoma1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer1
Esophageal Adenocarcinoma1
Esophageal Squamous Cell Cancer1
Siewert Type 1 GEJ Cancer1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Merck Sharp & Dohme LLC3
Seagen, a wholly owned subsidiary of Pfizer1
Taiho Oncology, Inc.1
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Levoleucovorin works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Levoleucovorin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.